Evotec SE (EVT.DE)

9,65 0,00 (0,00 %) À partir de 02:27PM CEST. Marché ouvert.

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 5 061

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Mario Polywka DPHIL, Ph.D.	CEO & Chairman of the Management Board & Member of the Supervisory Board	60k	S.O.	1963
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	582k	S.O.	1964
Dr. Craig Johnstone Ph.D.	COO & Member of Management Board	712k	S.O.	1970
Dr. Matthias Evers Ph.D.	Chief Business Officer & Member of Management Board	130k	S.O.	1973
Ms. Laetitia Rouxel	CFO & Member of Management Board	890k	S.O.	1975
Ms. Anja Bosler	Principal Accounting Officer and Senior Vice President of Group Accounting	S.O.	S.O.	S.O.
Mr. Volker Braun	Executive VP and Head of Global Investor Relations & ESG	S.O.	S.O.	S.O.
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	S.O.	S.O.	S.O.
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	S.O.	S.O.	S.O.
Dr. Ian M. Hunneyball	Senior Vice President of Programme Management & Clinical Operations	116k	S.O.	1950

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Evotec SE en date du 1 mai 2024 est 6. Les scores principaux sont Audit : 4; Société : 4; Droits des actionnaires : 1; Compensation : 7.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.